XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows – Operating activities:    
Net earnings, including noncontrolling interests $ 217,716 $ 137,744
Adjustments to reconcile net earnings (loss) to net cash provided (used) by operating activities:    
Depreciation 56,765 55,292
Amortization of intangible and other assets 6,482 7,782
Loss on sale of business 12,981 0
Stock-based compensation 24,608 22,127
Foreign currency, asset write downs and other non-cash adjustments 11,580 (11,827)
Change in assets and liabilities:    
Accounts receivable, net (96,402) 1,524
Inventories 2,944 (114,596)
Contract assets, net (23,293) (10,239)
Prepaid expenses and other, net 3,505 (6,727)
Accounts payable 24,654 1,910
Contract liabilities 8,466 15,879
Accrued liabilities (33,850) 21,429
Retirement obligations and other liabilities 8,696 38,838
Net deferred taxes 3,108 (27,996)
Net cash flows provided (used) by operating activities 227,960 131,140
Cash flows – Investing activities:    
Capital expenditures (52,169) (47,544)
Payments for disposition of business (2,555) 0
Other 612 (833)
Net cash flows provided (used) by investing activities (54,112) (48,377)
Cash flows – Financing activities:    
Payments on term loan (45,000) (30,000)
Proceeds under revolving credit facility 100,000 230,000
Payments under revolving credit facility (50,000) (145,000)
Proceeds under other financing arrangements 1,001 242
Payments under other financing arrangements (784) (2,098)
Repurchases of common shares (20,070) 0
Payments related to tax withholding for stock-based compensation (9,407) (6,203)
Payments of dividends (82,848) (78,712)
Other (272) (320)
Net cash flows provided (used) by financing activities (107,380) (32,091)
Effect of exchange rate changes on cash and cash equivalents (401) (5,185)
Net change in cash and cash equivalents 66,067 45,487
Cash and cash equivalents at beginning of period 545,678 434,971
Cash and cash equivalents at end of period $ 611,745 $ 480,458